Preclinical News and Research

RSS

Intercell receives FDA approval of IXIARO, novel vaccine for Japanese encephalitis

Intercell AG (VSE: ICLL) today announced that the U.S. Food and Drug Administration (FDA) approved IXIARO(R), a new vaccine for the prevention of Japanese Encephalitis (JE).

30 Mar 2009

Missing enzyme GNSOR conveys major heart protection in pre-clinical work

Mice born without a certain enzyme can resist the normal effects of a heart attack and retain nearly normal function in the heart's ventricles and still-oxygenated heart tissue, according to a study by researchers at Duke University Medical Center.

30 Mar 2009

Radius starts Ppase 2a trial of RAD1901 in menopausal hot flashes

Radius Health ("Radius") announced today that the first patient has been dosed in the company's proof-of-concept Phase 2a study of RAD1901, an investigational selective estrogen receptor modulator (SERM) undergoing clinical evaluation for treatment of vasomotor symptoms (menopausal hot flashes).

24 Mar 2009

Orexo reports on efficacy study in allergic rhinitis with OX914

Orexo has reported clinical results from an experimental phase IIa safety and efficacy study in allergic rhinitis with OX914, the first compound in its Phosphodiesterase 4 (PDE4) inhibitor program.

24 Mar 2009

Gilead commences phase II trial of Cicletanine for pulmonary arterial hypertension

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase II clinical trial of cicletanine hydrochloride (cicletanine), an oral agent in development for the treatment of pulmonary arterial hypertension (PAH).

24 Mar 2009

Researchers develop system to culture normal and cancerous pancreatic tissue isolated from resection specimens obtained from patients

Pancreatic cancer is a devastating disease with a very poor prognosis.

24 Mar 2009

Gold nanoparticles "cook" cancer cells

Researchers are describing a long-awaited advance toward applying the marvels of nanotechnology in the battle against cancer.

22 Mar 2009

Hollow gold nanospheres show promise in cancer therapy

A new metal nanostructure developed by researchers at the University of California, Santa Cruz, has already shown promise in cancer therapy studies and could be used for chemical and biological sensors and other applications as well.

22 Mar 2009

New TB vaccine developed using a genetically modified adenovirus

McMaster University researchers are about to launch Canada's first tuberculosis (TB) vaccine clinical trial with a vaccine totally designed, manufactured and tested within McMaster.

20 Mar 2009

Novel stimulation method sparks hope for Parkinson's disease sufferers

A novel stimulation method, the first potential therapy to target the spinal cord instead of the brain, may offer an effective and less invasive approach for Parkinson's disease treatment, according to pre-clinical data published in the journal Science by researchers at Duke University Medical Center.

20 Mar 2009

Synthesizing Vernix caseosa

Even after nine months soaking in the womb, a newborn's skin is smooth - unlike an adult's in the bath.

17 Mar 2009

FDA accepts IND for Arno Therapeutics' Pan-DAC / Akt inhibitor, AR-42

Arno Therapeutics, Inc. has announced that the U.S. Food and Drug Administration ("FDA") accepted the Company's Investigational New Drug ("IND") application for the use of AR-42.

17 Mar 2009

Drug being used to improve cognition affects dopamine, suggesting potential for abuse

Preliminary research in healthy men suggests that the narcolepsy drug modafinil, increasingly being used to enhance cognitive abilities, affects the activity of dopamine in the brain in a way that may create the potential for abuse and dependence, according to a study in the March 18 issue of JAMA.

17 Mar 2009

Alba Therapeutics announces next clinical trial of lead compound, Larazotide Acetate

Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

17 Mar 2009

Nobilon's intranasal influenza vaccine begins phase I clinical development

Nobilon, the human vaccine business unit of Schering-Plough Corporation has announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

15 Mar 2009

Cellular discovery may lead to targeted treatment for rare form of anemia

University of Cincinnati (UC) researchers have identified the specific biological mechanisms believed to lead to a rare and incurable blood disease known as Diamond Blackfan anemia (DBA).

15 Mar 2009

Alzheimer's disease therapeutic prevents long-term damage from TBI in pre-clinical studies

A class of Alzheimer's disease drugs currently studied in clinical trials appears to reduce damage caused by traumatic brain injury in animals, researchers at Georgetown University Medical Center report in an upcoming advance online publication of Nature Medicine.

15 Mar 2009

Phylonix granted broad U.S. patent for assessing cardiac functions in Zebrafish

Phylonix Pharmaceuticals announced, at the Society of Toxicology Annual Meeting in Baltimore, that the U.S. Patent and Trademark Office has issued the company a broad patent for assessing the toxicity of pharmaceutical test agents on cardiovascular functions in zebrafish.

15 Mar 2009

A model of melanoma generates hope for the use of targeted therapies

Researchers have developed a new mouse model that allows them to replicate normal pigment cells at the earliest stages of conversion to malignant skin cancer in humans.

12 Mar 2009

New investigational therapy for the treatment of bladder cancer

A team of researchers, led by Columbia University Medical Center faculty, has identified a new investigational therapy for the treatment of bladder cancer.

12 Mar 2009